Health & Fitness
Health and Fitness
Health and Fitness 
Tue, March 8, 2011
Mon, March 7, 2011
Kendall Law Group Investigates TomoTherapy Inc. Acquisition for Shareholders
DALLAS--([ BUSINESS WIRE ])--[ Kendall Law Group ], led by former federal judge Joe Kendall, is investigating TomoTherapy Inc. (NASDAQ: TOMO) for shareholders in connection with the proposed acquisition by Accuray Inc. The national securities firma™s investigation seeks to determine whether TomoTherapy and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are a TomoTherapy shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [ skendall@kendalllawgroup.com ].
On March 7, 2011, the companies announced the definitive merger agreement under which TomoTherapy would be acquired by Accuray, in a transaction valued at approximately $277 million. Under the terms of the agreement, TomoTherapy stockholders will receive $3.15 per share in cash and 0.1648 shares of Accuray (NASDAQ: ARAY) common stock for each share of TomoTherapy/TOMO common stock held. The consideration offered is valued at $4.80 per share, a premium of about 31 percent using Fridaya™s closing prices. According to Thompson/First Call, analysts have set a price target as high as $5.00 per share for TomoTherapy stock. The firma™s investigation seeks to determine whether TomoTherapy and its Board negotiated a deal that provides the best value available to shareholders.
Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.